HTA29 Analysis of the Change of the Added Benefit and Respective Reasons in Renewed Regular Benefit Assessments of Orphan Drugs Due to Exceeding the Sales Threshold in Germany
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1714
https://www.valueinhealthjournal.com/article/S1098-3015(23)04844-1/fulltext
Title :
HTA29 Analysis of the Change of the Added Benefit and Respective Reasons in Renewed Regular Benefit Assessments of Orphan Drugs Due to Exceeding the Sales Threshold in Germany
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04844-1&doi=10.1016/j.jval.2023.09.1714
First page :
Section Title :
Open access? :
No
Section Order :
11156